What Happened:
The 2026 Milliman Medical Index, released May 20, put the annual healthcare cost for a hypothetical family of four on an employer-sponsored plan at $37,824, up 7.9% year over year. The Workspan Daily roundup picked it up on May 29. The jump is the biggest single-year increase outside the pandemic in more than a decade.
It is the second cost data point in nine days. Mercer's 2026 National Survey projected a 6.5% increase in employer health benefit cost per employee, the highest in 15 years. Mercer captures what employers spend, Milliman captures the all-in cost of family coverage, and both numbers landed in the same direction.
The drivers are structural. Pharmacy costs jumped 14.8%, led by GLP-1 utilization and high-cost specialty drugs. Outpatient facility prices rose 7.5%. Those two categories account for 69% of the year-over-year increase.
More Insight:
The cost shift to employees is already moving. Mercer found that 59% of employers will make cost-cutting changes to their plans in 2026, up from 48% in 2025 and 44% in 2024. The most common move is the simplest one. Higher deductibles and higher cost-sharing on the employee side. Payroll deductions for coverage are expected to rise 6% to 7% on the same plan, in line with the overall increase.
Milliman attributes most of the 14.8% pharmacy spike to GLP-1 utilization and high-cost specialty drugs. GLP-1 coverage is the single benefits decision that has split total rewards teams for two years, and the 2026 numbers will not make it easier. Employers that added Zepbound and Wegovy for obesity in 2025 are now looking at year-two utilization curves with no clean way to walk the coverage back. The long-term cardiovascular savings case is still emerging, the 12-month adherence research is still thin, and the headcount on coverage has already crossed a political threshold inside most companies.
Outpatient facility prices are the second pressure point. The 7.5% increase reflects hospital pricing power on the services that moved from inpatient wards into outpatient surgery centers over the last decade. Steerage to high-quality, low-cost sites of care is the lever benefits leaders still have on this side of the ledger, and the centers of excellence playbook is moving from optional to a default 2027 RFP requirement at larger employers.
Both reports describe the same structural forces. Pharmacy innovation that does not get cheaper, hospital pricing power that does not unwind, utilization that did not normalize after COVID. Total rewards leaders building the 2027 plan are setting their budgets against that multi-year baseline.